Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) arises from collateral damage to peripheral afferent sensory neurons by anticancer pharmacotherapy, leading to debilitating neuropathic pain. No effective treatment for CIPN exists, short of dose-reduction which worsens cancer prognosis. Here, we rep...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
eLife Sciences Publications Ltd
2017-11-01
|
| Series: | eLife |
| Subjects: | |
| Online Access: | https://elifesciences.org/articles/29626 |
| _version_ | 1818024007397539840 |
|---|---|
| author | Peter M LoCoco April L Risinger Hudson R Smith Teresa S Chavera Kelly A Berg William P Clarke |
| author_facet | Peter M LoCoco April L Risinger Hudson R Smith Teresa S Chavera Kelly A Berg William P Clarke |
| author_sort | Peter M LoCoco |
| collection | DOAJ |
| description | Chemotherapy-induced peripheral neuropathy (CIPN) arises from collateral damage to peripheral afferent sensory neurons by anticancer pharmacotherapy, leading to debilitating neuropathic pain. No effective treatment for CIPN exists, short of dose-reduction which worsens cancer prognosis. Here, we report that stimulation of nicotinamide phosphoribosyltransferase (NAMPT) produced robust neuroprotection in an aggressive CIPN model utilizing the frontline anticancer drug, paclitaxel (PTX). Daily treatment of rats with the first-in-class NAMPT stimulator, P7C3-A20, prevented behavioral and histologic indicators of peripheral neuropathy, stimulated tissue NAD recovery, improved general health, and abolished attrition produced by a near maximum-tolerated dose of PTX. Inhibition of NAMPT blocked P7C3-A20-mediated neuroprotection, whereas supplementation with the NAMPT substrate, nicotinamide, potentiated a subthreshold dose of P7C3-A20 to full efficacy. Importantly, P7C3-A20 blocked PTX-induced allodynia in tumored mice without reducing antitumoral efficacy. These findings identify enhancement of NAMPT activity as a promising new therapeutic strategy to protect against anticancer drug-induced peripheral neurotoxicity. |
| first_indexed | 2024-12-10T03:53:22Z |
| format | Article |
| id | doaj.art-b194baab3c214d438f751db3cabb69d4 |
| institution | Directory Open Access Journal |
| issn | 2050-084X |
| language | English |
| last_indexed | 2024-12-10T03:53:22Z |
| publishDate | 2017-11-01 |
| publisher | eLife Sciences Publications Ltd |
| record_format | Article |
| series | eLife |
| spelling | doaj.art-b194baab3c214d438f751db3cabb69d42022-12-22T02:03:11ZengeLife Sciences Publications LtdeLife2050-084X2017-11-01610.7554/eLife.29626Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathyPeter M LoCoco0https://orcid.org/0000-0002-5678-791XApril L Risinger1https://orcid.org/0000-0002-4363-3268Hudson R Smith2Teresa S Chavera3Kelly A Berg4William P Clarke5https://orcid.org/0000-0002-8861-8256Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, United StatesDepartment of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, United StatesDepartment of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, United StatesDepartment of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, United StatesDepartment of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, United StatesDepartment of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, United StatesChemotherapy-induced peripheral neuropathy (CIPN) arises from collateral damage to peripheral afferent sensory neurons by anticancer pharmacotherapy, leading to debilitating neuropathic pain. No effective treatment for CIPN exists, short of dose-reduction which worsens cancer prognosis. Here, we report that stimulation of nicotinamide phosphoribosyltransferase (NAMPT) produced robust neuroprotection in an aggressive CIPN model utilizing the frontline anticancer drug, paclitaxel (PTX). Daily treatment of rats with the first-in-class NAMPT stimulator, P7C3-A20, prevented behavioral and histologic indicators of peripheral neuropathy, stimulated tissue NAD recovery, improved general health, and abolished attrition produced by a near maximum-tolerated dose of PTX. Inhibition of NAMPT blocked P7C3-A20-mediated neuroprotection, whereas supplementation with the NAMPT substrate, nicotinamide, potentiated a subthreshold dose of P7C3-A20 to full efficacy. Importantly, P7C3-A20 blocked PTX-induced allodynia in tumored mice without reducing antitumoral efficacy. These findings identify enhancement of NAMPT activity as a promising new therapeutic strategy to protect against anticancer drug-induced peripheral neurotoxicity.https://elifesciences.org/articles/29626neuropathychemotherapypainneurotoxicityneuroprotectionNAMPT |
| spellingShingle | Peter M LoCoco April L Risinger Hudson R Smith Teresa S Chavera Kelly A Berg William P Clarke Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy eLife neuropathy chemotherapy pain neurotoxicity neuroprotection NAMPT |
| title | Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy |
| title_full | Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy |
| title_fullStr | Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy |
| title_full_unstemmed | Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy |
| title_short | Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy |
| title_sort | pharmacological augmentation of nicotinamide phosphoribosyltransferase nampt protects against paclitaxel induced peripheral neuropathy |
| topic | neuropathy chemotherapy pain neurotoxicity neuroprotection NAMPT |
| url | https://elifesciences.org/articles/29626 |
| work_keys_str_mv | AT petermlococo pharmacologicalaugmentationofnicotinamidephosphoribosyltransferasenamptprotectsagainstpaclitaxelinducedperipheralneuropathy AT aprillrisinger pharmacologicalaugmentationofnicotinamidephosphoribosyltransferasenamptprotectsagainstpaclitaxelinducedperipheralneuropathy AT hudsonrsmith pharmacologicalaugmentationofnicotinamidephosphoribosyltransferasenamptprotectsagainstpaclitaxelinducedperipheralneuropathy AT teresaschavera pharmacologicalaugmentationofnicotinamidephosphoribosyltransferasenamptprotectsagainstpaclitaxelinducedperipheralneuropathy AT kellyaberg pharmacologicalaugmentationofnicotinamidephosphoribosyltransferasenamptprotectsagainstpaclitaxelinducedperipheralneuropathy AT williampclarke pharmacologicalaugmentationofnicotinamidephosphoribosyltransferasenamptprotectsagainstpaclitaxelinducedperipheralneuropathy |